Windlas Biotech Limited has successfully concluded its Board of Directors meeting held on April 17, 2026, approving a comprehensive share buyback proposal worth ₹470 crore. The pharmaceutical company announced the outcome through regulatory filings to stock exchanges under Regulation 30 and Regulation 42 of SEBI LODR Regulations, marking a significant corporate action for shareholders.

Buyback Approval Details

The board has approved the buyback of up to 4,70,000 fully paid-up equity shares, each having a face value of ₹5.00, representing 2.23% of the total equity shares in the existing paid-up equity share capital. The buyback will be conducted at a price of ₹1,000 per equity share, payable in cash, representing 9.80% of the aggregate total paid-up equity share capital and free reserves based on audited financial statements as at March 31, 2025.

Record Date and Regulatory Framework

Pursuant to Regulation 42 of SEBI LODR Regulations and Regulation 9(i) of SEBI Buy-Back Regulations, Friday, April 24, 2026, has been fixed as the record date for determining shareholder eligibility. The buyback will be conducted through the "Tender Offer" route as prescribed under SEBI Buy-Back Regulations, 2018, with 15% of the buyback quantity reserved for small shareholders.

Current Shareholding Pattern

As of March 31, 2026, the company's pre-buyback shareholding structure shows promoters and promoter group holding 1,30,65,352 shares representing 61.90% of the total paid-up capital. The total number of shareholders stands at 44,769 with 2,11,06,229 equity shares outstanding.

Management and Compliance Structure

The board has constituted a buyback committee with delegated powers to execute all necessary actions for the buyback process. Mr. Ananta Narayan Panda, Company Secretary, has been appointed as the Compliance Officer for the proposed buyback. Fintellectual Corporate Advisors Private Limited, a SEBI registered merchant banker, has been appointed as the Manager to the Buyback.

The promoters and members of the promoter group have indicated their intention not to participate in the proposed buyback. The board retains flexibility to increase the buyback price and decrease the number of shares till one working day prior to the record date, ensuring no change in the aggregate buyback size. The public announcement and letter of offer detailing the complete process, timelines, and other requisite details will be released in accordance with SEBI Buyback Regulations.

Windlas Biotech Limited has announced a scheduled virtual meeting with analysts and institutional investors, set to take place on April 20, 2026. The pharmaceutical company formally notified both BSE Limited and National Stock Exchange of India Limited about this investor engagement on April 15, 2026.

Meeting Details and Schedule

The company has organized a group investor meeting with the following specifications:

Regulatory Compliance and Information Sharing

The notification was issued pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Windlas Biotech has explicitly stated that the company will reference only publicly available documents during discussions with investors and analysts.

The company has provided clear assurance that no unpublished price sensitive information (UPSI) will be shared during the meeting, maintaining compliance with regulatory requirements for investor interactions.

Administrative Details

Company Secretary and Compliance Officer Ananta Narayan Panda signed the official notification, acknowledging that potential schedule changes may occur due to exigencies on the part of investors, analysts, or the company itself. The notification was formally submitted to both major Indian stock exchanges on April 15, 2026.

This investor meeting represents part of Windlas Biotech's ongoing engagement with the investment community, providing a platform for discussions about the company's operations and performance based on publicly disclosed information.